RxDoctor Payments Data

Milan Kahanda, MD

Clinical Cardiac Electrophysiology · Saint Louis, MONPI 1811301740

Payments from drug & device makers

What this record shows

This record is dominated by grants: $29,294 of the $44,764 with a category attached, or 65.4%. 16 manufacturers reported payments, led by Medtronic at 45.6% of the total. Reporting peaked in 2020 at $20,269 and has fallen 81.5% since, to $3,751 in 2025.

$44,764in general payments, 2019–2025

Across 305 payments — averaging $146.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Abbott$13K
  • Boston Scientific$6K
  • Medical Device Business Services, Inc.$3K
  • Biosense Webster, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$218
  • plus $484 from 10 others

What the payments were for

  • Grants$29,29465%
  • Travel & lodging$7,25116%
  • Food & beverage$7,88818%
  • Education$3311%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,764 in reported general payments places this provider in the 85th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$70,130
Medicare patients
381
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$143,290
MultaqDronedarone Hcl28$31,824
XareltoRivaroxaban32$31,437
Amiodarone Hcl103$4,406
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,796
Dofetilide12$2,502
Flecainide Acetate49$1,703
Mexiletine Hcl13$1,480
Metoprolol Succinate133$1,278
Dilt-XrDiltiazem Hcl20$490
Metoprolol Tartrate89$340
SotalolSotalol Hcl13$286
Carvedilol43$162
Pantoprazole Sodium23$108
Losartan Potassium15$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$143,290163 claims
Sanofi-aventis U.S. LLCMultaq$53$31,82428 claims
Johnson & JohnsonXarelto$19$31,43732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →